About ERIX
EiRx Therapeutics is a specialist provider of pre-clinical therapeutics to the pharmaceutical industry. Our unique scientific expertise and knowledge in the field of Apoptosis provide a sound base to discover and develop new medicines that will safely and selectively repair this natural process in disease. The potential benefits from these new medicines are enormous, since as many as 70% of all human disease have some defect in the control of Apoptosis.
Apoptosis - the biological process that determines whether cells in our bodies live or die...
http://www.eirx.com/index.html

Purchased some of these on the strength of the PROGRESS UPDATE looks promising.
http://moneyam.uk-wire.com/cgi-bin/articles/200603200701130254A.html

ERX interview with John Pool
http://www.wallstreetreporter.com/interview.php?id=18589&player=real
Latest News
CANCER COLLABORATION WITH BIOMERIEUX SA
http://moneyam.uk-wire.com/cgi-bin/articles/200607120700230534G.html
Biomerieux Web Site
http://www.biomerieux.com/servlet/srt/bio/portail/home
ABOUT ERX Focus Of The Month
http://www.billamag.net/focus-document-text.asp?FocusTextID=1
ERX pdf filehttp://www.eirx.com/eirx_heading_images/Yokohama2005.pdf
19/09/2006 A 50% reduction in breast tumour volume size seen with Eirx lead molecule in animal studies
http://moneyam.uk-wire.com/cgi-bin/articles/200609190700171175J.html

Past and present collaborative partners include:

* bioMieux SA
* Almac Diagnostics Ltd
* Merck & Co, Ltd
* Biofocus plc
* MGI Pharmaceuticals, Inc
* OSI Pharmaceuticals, Inc
* Sareum plc
* Regen Therapeutics plc
* SR Pharma plc

Driver, a good day of buying and still the sp drops ?? WHY DO YOU THINK !

smiler
mms playing their games to get you to sell or a more attractive sp for the buyers they win every time.

I hope the news is tomorrow, we need positive momentum, there is loads of news to come

Kyowa Hakko Grants Keryx Biopharmaceuticals Exclusive Rights to UCN-01, a Novel, Anticancer Agent in Phase II Clinical Development



NEW YORK, October 04, 2006 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. today announced that it has entered into an exclusive license agreement with Kyowa Hakko Kogyo Co., Ltd. (Kyowa Hakko), of Tokyo, Japan, for the worldwide development and commercialization rights, excluding Japan, to UCN-01 (7-hydroxystaurosporine). UCN-01 is a novel multi-kinase inhibitor for the treatment of cancer which, in preclinical models, has demonstrated a synergistic effect with agents inhibiting the PI3K pathway, including perifosine. UCN-01 is currently in several Phase II clinical trials both as a single agent and in combination with other anticancer agents which are being conducted under the direction and sponsorship of the National Cancer Institute. In accordance with the terms of the agreement, Keryx will make up-front and milestone payments as well as pay royalties on product sales.



Commenting on the in-licensing of UCN-01, I. Craig Henderson, MD, the Company's President, stated "We are excited about this drug because it targets some of the most interesting pathways involved in the propagation and survival of cancer cells and complements our ongoing program with KRX-0401 (perifosine)."

ABOUT UCN-01

UCN-01 is an anticancer drug that belongs to the family of drugs called staurosporine analogs which have demonstrated an ability to inhibit multiple kinases involved in cell-cycle progression and apoptosis, including Chk-1 and PDK1. In pre-clinical studies, UCN-01 has demonstrated synergistic effect with DNA-damaging agents including chemotherapy and radiation therapy. In-vitro, UCN-01 has been shown to be synergistic with agents affecting the PI3-K pathway including perifosine and mTOR inhibitors. In clinical trials, as reported by investigators at the National Cancer Institute, durable single-agent responses have been seen in patients with anaplastic large-cell lymphoma.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals, Inc. is focused on the acquisition, development and commercialization of novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx's lead compound under development is Sulonex(TM), previously referred to as KRX-101, a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes. Sulonex is in a pivotal Phase III and Phase IV clinical program under a Special Protocol Assessment with the Food & Drug Administration. Additionally, Keryx is developing Zerenex(TM), an oral, inorganic, iron-based compound that has the capacity to bind phosphate and form non-absorbable complexes. Zerenex is currently in Phase II clinical development for the treatment of hyperphosphatemia (elevated serum phosphorous levels) in patients with end-stage renal disease. Keryx is also developing clinical-stage oncology compounds, including KRX-0401 (perifosine), a novel, first-in-class, oral modulator of Akt, a pathway associated with tumor survival and growth, and other important signal transduction pathways. KRX-0401 (perifosine) is currently in Phase II clinical development for multiple tumor types. Keryx also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.

up we go, should start to fly now

fill ya booties.. this is going to go up alot..

fill ya booties.. this is going to go up alot..

Steady as she goes PH

Up a tad driver, might make up some of my loss on FAO !!! :)

Financial Review March 2005

Expenditure in the six months ended 31 December 2004 totalled 595,567, (2003; Nil) including 122,136 of goodwill amortisation, 76,152 of depreciation of equipment and patents and a currency translation gain of 48,501.

At the end of the period cash at bank and in hand amounted to 19,890 and 135,000 was due from its parent company, EiRx Pharma Limited. Just after the end of the period a placing of shares raised 550,000. The funds raised will be used to provide additional working capital for the EiRx group and to continue the development of its drug discovery programme.

Prospects

There are a number of trends that will dominate EiRxs profile in the second half of its financial year and beyond. Development and commercialisation of drug candidates generated from within EiRx lies at the core of the business. Licensed-in products are likely to grow in importance. Auvation for example has licensed rights to develop diagnostic and immunotherapy applications for a tumour marker protein, to the Massachusetts-based drug development company Zycos Inc. Zycos, which was recently acquired by MGI Pharma, has completed a Phases 1/IIa study and expects to take the compound into Phase II trials in patents with solid tumours later this year. Further milestone payments would be due to Auvation at that time.

Acquisitions are expected to continue as EiRx looks to build on its range of expertise, technologies and customer exposure.

Just over a year since EiRx joined AIM, the business is making full use of the opportunities a public listing provides. These are exciting times. We are building from a small base, but it is a sound one at the cutting-edge of drug discovery technology.

John Pool
Chairman
http://www.eirx.com/eirx_pages/chairstatement.htm

As usual I had to do all the bloody work

Like I said, phase III is probably complete

Pharmaceutical Research and Manufacturers of America
application submitted/Phase III/Phase II NCI Trial/Phase I NCI Trial ... Seattle, WA. Phase I/Phase III. ZYC300 none / none. Cancer, Metastatic Melanoma ...
international.phrma.org/newmedicines/ newmedsdb/drugs.cfm?indicationcode=Solid%20tumors%7C1220 - 203k - Cached - Similar pages

http://www.mgipharma.com/wt/page/pipeline

ZYC300.. expect news very shortly, its our baby

Glad to see broker at the side of that 40 million sale.

MGI are being chased by ERX for mileston payment according to company, MGI pharma report results on wednesday.. expect great news!!!

Protein May Help Targeting for Anti-Tumor Drugs
21:35:11 EDT Oct 12, 2006
Canadian Press
THURSDAY, Oct. 12 (HealthDay News) - A protein that may help in the development of new anti-tumor drugs has been identified by Mayo Clinic researchers.

The protein - cyclin-dependent kinase 2 (CDK2) - acts as a "quality control inspector" during cell division, and also directs cell death for cells that are damaged during division.

Normal cells pause during the division process if they detect an inaccurate genetic code embedded in their DNA. If possible, repairs are made to those mistakes.

When those genetic code errors are irreparable, CDK2 modifies another cellular protein called FOX01 to send a signal that causes the damaged cell to die, the study found.

"Quality control within dividing cells is essential because mistakes during duplication of the genetic code can lead to cancer. CDK2 is a key protein component in the cellular mechanism that leads to repair of damaged DNA," Donald Tindall, co-leader of the Mayo Clinic Cancer Center prostate cancer research program, said in a prepared statement.

This finding offers scientists a potential "bulls eye" for targeting anti-tumor drugs.

The study was published in the current issue of Science.

MGI are being chased by ERX for mileston payment according to company, MGI pharma report results on wednesday.. expect great news!!!

Pharmaceutical Feature: Cdk5 inhibitors as novel candidate ...Hawkings, EF Medical, EiRx Therapeutics Ltd, Elan IT, Eli Lilly ... Cdk5 differs from other members of the Cdk family being modulated by its activator, p35. ...

http://www.google.co.uk/search?hl=en&ned=uk&ie=UTF-8&q=CDK2+eirx&sa=N&tab=nw

Serono Sa European pharma mergers set to continue - S&P
LONDON (AFX) - The recent wave of mergers among European pharmaceutical
companies is set to continue, Standard & Poor's believes, driven by strong
global sales growth and the race to develop top-selling "blockbuster" drugs.
The recent surge of activity started in July, when Germany's Bayer AG bought
domestic rival Schering AG in a deal worth nearly 16.9 bln eur.
Since then Merck KGaA, which lost out in the battle for Schering, has bought
the majority stake in Switzerland's Serono SA for 16.6 bln sfr, Nycomed acquired
the pharmaceutical arm of Altana AG for 4.5 bln eur and Belgium's UCB swooped on
Schwarz Pharma AG, paying 4.4 bln eur.
Standard & Poor's Olaf Toelke said those deals, among mid-sized companies,
mainly reflect concerns about critical size.
"All the transactions, including the Bayer-Schering link-up, have taken
place in a market dominated by the need to fund ever-increasing R&D budgets in
the race for the next blockbuster drug," the credit analyst wrote.
A key concern for pharma companies at the moment is the productivity of
their research and development efforts. The cost of developing a new drug has
risen in the last 10 years, as research techniques and compounds have become
more complicated, and regulatory requirements more onerous.
Taking into account all the products that never make it to the market, the
cost of developing every drug that does reach the shelves is estimated at more
than 1 bln usd.
Medium-sized drug makers such as Merck KGaA and Serono, which do not have
the huge cash flow of large pharma groups, have been merging so R&D budgets can
be increased.
Meanwhile, S&P said that the larger European pharmaceutical companies'
above-industry-average global sales growth and strong cash generation is
increasing their flexibility for M&A activities.
Companies including Switzerland's Roche Holding AG and Britain's
GlaxoSmithKline PLC reported sales growth of about 10 pct in the second quarter
of 2006, compared with an average assumed industry growth of about 6-7 pct, they
noted.
"The rated companies should therefore experience a further strengthening of
their credit quality on average, in the absence of larger acquisitions," Toelke
wrote.
amy.brown@afxnews.com
ab/lam

MGI phara results out wednesday news on milestone payment to ERX expected for its trial of ZYC300

MGI Pharma
----------
http://www.eirx.com/eirx_heading_images/Vaccine%20Antigens%20v2.0.pdf#search=%22mgi%20pharma%20zyc300%22

http://www.mgipharma.com/

last chance tomorrow... MGI announce on 18th

Hello pot head, some good trading to day!! might see 1p on some positive news :)

I think it will go higher than that mate.. colorectal cancer news will be huge, it will show just how undervalued this is